Nuvation Bio (NUVB) Cash & Equivalents (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Cash & Equivalents of $125.4 million for Q1 2026, up 161.36% year-over-year from $48.0 million in Q1 2025, and down 23.58% quarter-over-quarter from $164.1 million in Q4 2025.
Nuvation Bio (NUVB) Cash & Equivalents (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Cash & Equivalents for 7 consecutive years, with $125.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents rose 161.36% year-over-year to $125.4 million; the TTM figure through Mar 2026 stood at $125.4 million (up 161.36% YoY), while the FY2025 annual figure was $164.1 million, up 359.33% from the prior year.
- Cash & Equivalents declined to $125.4 million in Q1 2026 per NUVB's latest filing, from $164.1 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $248.0 million in Q2 2025 and bottomed at $24.4 million in Q3 2023.
- Historically, Cash & Equivalents has averaged $83.2 million across 5 years, with a median of $50.1 million in 2023.
- Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 83.38% — and 2025, when it jumped 623.26%.
- Nuvation Bio's Cash & Equivalents stood at $101.1 million in 2022, then slumped by 57.81% to $42.6 million in 2023, then declined by 16.24% to $35.7 million in 2024, then soared by 359.33% to $164.1 million in 2025, then retreated by 23.58% to $125.4 million in 2026.
- Business Quant data shows NUVB's Cash & Equivalents at $125.4 million in Q1 2026, $164.1 million in Q4 2025, and $98.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn | 258.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 258.60 Mn |
| Mar 31, 2026 | 125.39 Mn |
| Dec 31, 2025 | 164.09 Mn |
| Sep 30, 2025 | 98.90 Mn |
| Jun 30, 2025 | 247.97 Mn |
| Mar 31, 2025 | 47.98 Mn |
| Dec 31, 2024 | 35.72 Mn |
| Sep 30, 2024 | 30.04 Mn |
| Jun 30, 2024 | 34.29 Mn |
| Mar 31, 2024 | 34.51 Mn |
| Dec 31, 2023 | 42.65 Mn |
| Sep 30, 2023 | 24.40 Mn |
| Jun 30, 2023 | 50.07 Mn |
| Mar 31, 2023 | 30.07 Mn |
| Dec 31, 2022 | 101.10 Mn |
| Sep 30, 2022 | 138.69 Mn |
| Jun 30, 2022 | 102.32 Mn |
| Mar 31, 2022 | 106.21 Mn |
| Dec 31, 2021 | 132.42 Mn |
| Sep 30, 2021 | 344.63 Mn |